Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 302

1.

An OPTIMIZE Study Retrospective Analysis for the Management of Telaprevir-Treated HCV Patients Using the Abbott RealTime HCV RNA Assay.

Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, Witek J, Buti M, Picchio G, De Meyer S.

J Clin Microbiol. 2015 Feb 4. pii: JCM.03030-14. [Epub ahead of print]

PMID:
25653396
[PubMed - as supplied by publisher]
2.

Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.

Buti M, Tabernero D, Mas A, Homs M, Prieto M, Rodríguez-Frías F, Casafont F, Casillas R, González A, Miras M, Herrero JI, Castells L, Esteban R.

Transpl Infect Dis. 2015 Feb 2. doi: 10.1111/tid.12360. [Epub ahead of print]

PMID:
25641570
[PubMed - as supplied by publisher]
3.

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection.

Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Mani Subramanian G, Gane E, Marcellin P.

Dig Dis Sci. 2014 Dec 23. [Epub ahead of print]

PMID:
25532501
[PubMed - as supplied by publisher]
4.

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.

Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, Schuchmann M, Manns M, Bourlière M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Böcher W, Mensa FJ.

Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91. doi: 10.1128/AAC.04383-14. Epub 2014 Dec 15.

PMID:
25512403
[PubMed - in process]
5.

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Buti M, Flisiak R, Kao JH, Chuang WL, Streinu-Cercel A, Tabak F, Calistru P, Goeser T, Rasenack J, Horban A, Davis GL, Alberti A, Mazzella G, Pol S, Orsenigo R, Brass C.

J Viral Hepat. 2014 Nov 21. doi: 10.1111/jvh.12360. [Epub ahead of print]

PMID:
25412795
[PubMed - as supplied by publisher]
6.

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.

Dierynck I, Ghys A, Witek J, Luo D, Janssen K, Daems B, Picchio G, Buti M, De Meyer S.

J Viral Hepat. 2014 Dec;21(12):835-42. doi: 10.1111/jvh.12347.

PMID:
25402544
[PubMed - in process]
7.

Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution.

Homs M, Caballero A, Gregori J, Tabernero D, Quer J, Nieto L, Esteban R, Buti M, Rodriguez-Frias F.

PLoS One. 2014 Nov 13;9(11):e112306. doi: 10.1371/journal.pone.0112306. eCollection 2014.

PMID:
25393280
[PubMed - in process]
Free PMC Article
8.

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods.

Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, del Campo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI.

J Clin Microbiol. 2015 Jan;53(1):219-26. doi: 10.1128/JCM.02093-14. Epub 2014 Nov 5.

PMID:
25378574
[PubMed - in process]
9.

[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].

Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, Casado MA.

Farm Hosp. 2014 Sep 16;38(5):418-29. doi: 10.7399/fh.2014.38.5.7640. Spanish.

PMID:
25344136
[PubMed - in process]
Free Article
10.

Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.

Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, Diago M, Bonet L, Gallego A, García-Samaniego J, Testillano M, Rodríguez M, Castellano G, Gutiérrez ML, Delgado M, Mas A, Romero-Gómez M, Calleja JL, González-Guirado A, Arenas JI, García-Buey L, Andrade R, Gila A; ORIENTE-2 study group.

Eur J Gastroenterol Hepatol. 2015 Jan;27(1):46-54. doi: 10.1097/MEG.0000000000000195.

PMID:
25341057
[PubMed - in process]
11.

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).

Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P.

Liver Int. 2015 Feb;35(2):422-8. doi: 10.1111/liv.12694. Epub 2014 Oct 28.

PMID:
25277773
[PubMed - in process]
12.

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.

Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, Taunk J, Stern JO, Vinisko R, Gallivan JP, Böcher W, Mensa FJ; SOUND-C3 study group.

Liver Int. 2015 Feb;35(2):417-21. doi: 10.1111/liv.12693. Epub 2014 Oct 16.

PMID:
25263751
[PubMed - in process]
13.

Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.

Buti M, Esteban R.

Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):375-85. doi: 10.1586/17474124.2015.960396. Epub 2014 Sep 15.

PMID:
25222289
[PubMed - in process]
14.

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P.

J Hepatol. 2015 Feb;62(2):363-70. doi: 10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6.

PMID:
25195548
[PubMed - in process]
15.

Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.

Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E.

Dig Dis Sci. 2015 Jan;60(1):260-8. doi: 10.1007/s10620-014-3336-7. Epub 2014 Sep 2.

PMID:
25179493
[PubMed - in process]
16.

Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.

Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis.

Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15.

PMID:
25113158
[PubMed - in process]
17.

Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection.

Riveiro-Barciela M, Buti M, Homs M, Campos-Varela I, Cantarell C, Crespo M, Castells L, Tabernero D, Quer J, Esteban R, Rodriguez-Frías F.

PLoS One. 2014 Jul 28;9(7):e103028. doi: 10.1371/journal.pone.0103028. eCollection 2014.

PMID:
25068388
[PubMed - in process]
Free PMC Article
18.

[Hepatitis B virus infection in pregnancy and the immunosuppressed patient].

Riveiro-Barciela M, Buti M.

Gastroenterol Hepatol. 2015 Jan;38(1):31-9. doi: 10.1016/j.gastrohep.2014.05.011. Epub 2014 Jul 25. Spanish.

PMID:
25066320
[PubMed - in process]
19.

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ.

J Hepatol. 2014 Dec;61(6):1228-37. doi: 10.1016/j.jhep.2014.07.019. Epub 2014 Jul 18.

PMID:
25046847
[PubMed - in process]
20.

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.

Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; for the VIRGIL Surveillance Study Group.

Gut. 2014 Jul 10. pii: gutjnl-2014-307023. doi: 10.1136/gutjnl-2014-307023. [Epub ahead of print]

PMID:
25011935
[PubMed - as supplied by publisher]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk